Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
1.560
+0.090 (6.12%)
At close: Aug 29, 2024, 4:00 PM
1.530
-0.030 (-1.92%)
After-hours: Aug 29, 2024, 7:57 PM EDT
Company Description
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Silexion Therapeutics Corp
| Country | Israel |
| Founded | 2008 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Ilan Hadar |
Contact Details
Address: The Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center Jerusalem, 9112001 Israel | |
| Phone | 972 2 674 3430 |
| Website | silexion.com |
Stock Details
| Ticker Symbol | SLXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002022416 |
| ISIN Number | KYG1281K1067 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ilan Levin | Chairman of the Board, Chief Executive Officer and Secretary |
| Craig J. Marshak | Co-Founder and Vice Chairman |
| Gil Maman | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 29, 2024 | 10-Q | Quarterly Report |
| Aug 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 15, 2024 | CERT | Certification by an exchange approving securities for listing |
| Aug 15, 2024 | 8-A12B | Registration of securities |
| Jul 25, 2024 | 425 | Filing |
| Jul 17, 2024 | 424B3 | Prospectus |
| Jul 16, 2024 | EFFECT | Notice of Effectiveness |
| Jul 12, 2024 | S-4/A | Filing |